CD274 and ovarian cancer: A phase I/II study of Vigil examining the efficacy of a GM-CSF-secreting autologous tumor cell vaccine demonstrated extended PFS in combination with durvalumab in recurrent ovarian cancer patients with PD-L1 expression, highlighting the synergistic potential of combining these modalities [55].